The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients

NCT ID: NCT02049658

Last Updated: 2024-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies have demonstrated that sniff dogs can identify cancer patients from healthy subjects through sniffing exhaled breath air or blood or serum or urine or feces. It is hypothesized that sniff dogs may be used as a tool in identifying cancer patients in the high risk population or suspected patients. Trained dogs will sniff serum from participants who are suspected to suffer from tumor by their physicians and not yet but will be diagnosed by pathological examination.The results will be compared with the outcome of the pathological examination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

Healthy volunteers measured by currently used healthy screening procedures

No interventions assigned to this group

Suspected breast cancer subjects

Suspected breast cancer subjects without pathological examination yet but will have it soon

No interventions assigned to this group

Suspected lung cancer subjects

Suspected lung cancer subjects without pathological examination yet but will have it soon

No interventions assigned to this group

Suspected neurological tumor subjects

Suspected neurological tumor subjects without pathological examination yet but will have it soon

No interventions assigned to this group

Suspected patients with gynecological tumor

Suspected subjects with gynecological tumors without pathological examination yet but will have it soon

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers who have been examined by the currently used procedures and find to be without tumors.
* Patients in the breast surgery, thoracic surgery, gynecological and neurosurgery departments with lesions with characteristics of tumors

Exclusion Criteria

* Patients who have had pathological results
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chang-Qing Gao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chang-Qing Gao

MD PhD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chang-Qing Gao, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Central South University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Scientific Research with Animal Models, CSU

Changsha, Hunan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chang-Qing Gao, MD PhD

Role: CONTACT

86 188 7486 9488

Ya-Qin Wang, MD PhD

Role: CONTACT

86 15274810930

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chang-Qing Gao, MD PhD

Role: primary

86 188 7486 9488

Ya-Qin Wang, MD PhD

Role: backup

152 7481 0930

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XY 0003

Identifier Type: -

Identifier Source: secondary_id

Xiang-Ya 0003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.